Contents

11 January 2017
Vol 9, Issue 372
  • Perspective

    • Disruptive reproductive technologies

      In vitro gametogenesis raises new possibilities for reproductive and regenerative medicine as well as vexing policy challenges.

  • Research Articles

    • Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function

      Inhibiting Aurora kinase A and JAK2 signal transduction pathways permits the differentiation of potent regulatory T cells while neutralizing alloreactive T cells and preventing graft-versus-host disease without impairing antitumor responses.

    • Post hoc assessment of the immunogenicity of bioengineered factor VIIa demonstrates the use of preclinical tools

      A computational and experimental strategy assesses the immunogenicity risk of bioengineered therapeutic proteins.

    • A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions

      PTK7 is a tumor-initiating cell antigen, which can be targeted with an antibody-drug conjugate to confer sustained tumor regressions.

    • Pharmacological rescue of diabetic skeletal stem cell niches

      Local delivery of a missing growth factor to the skeletal stem cell niche restores bone healing in diabetic mice.

    • CRISPR-Cas9 gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease

      CRISPR-mediated gene repair of hematopoietic stem cells from patients with X-linked chronic granulomatous disease resulted in functional human leukocytes in mice after transplantation.

  • Editors Choice

    • Tune into the rhythm of your bugs

      Diurnal changes in gut microbiota localization and function alter host physiology through circadian epigenetic and transcriptional changes.

    • A weighty problem

      Altered dopamine signaling in obesity might decrease physical activity without contributing to weight gain.

About The Cover

Cover image expansion

ONLINE COVER Lighting a Path to GVHD Prevention. Pictured here is the Aurora borealis, a natural light display visible near the North Pole. Targeting Aurora kinase A and Janus kinase 2 with a small molecule inhibitor resulted in blunting of donor T cell activation after stem cell transplantation in mice with a human immune system (Betts et al.). Inactivating these kinases drove human T cells toward a regulatory phenotype and prevented graft-versus-host disease in the humanized mice. Importantly, T cells treated with the inhibitor were still able to kill tumor cells, suggesting that patients receiving this treatment could still mount a crucial antileukemia response if a relapse occurred. [CREDIT: KEVIN SCHAFER/ALAMY STOCK PHOTO]